SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. You have free access to this content1
    Konstantinos Stamatiou, Editorial Comment to Estimating age and ethnic variation in the histological prevalence of prostate cancer to inform the impact of screening policies, International Journal of Urology, 2014, 21, 8
  2. You have free access to this content2
    Carol DeSantis, Deepa Naishadham, Ahmedin Jemal, Cancer statistics for African Americans, 2013, CA: A Cancer Journal for Clinicians, 2013, 63, 3
  3. 3
    Christopher J. Weight, Simon P. Kim, Debra J. Jacobson, Michaela E. McGree, R. Jeffrey Karnes, Jennifer St. Sauver, Men (Aged 40-49 Years) With a Single Baseline Prostate-specific Antigen Below 1.0 ng/mL Have a Very Low Long-term Risk of Prostate Cancer: Results From a Prospectively Screened Population Cohort, Urology, 2013, 82, 6, 1211

    CrossRef

  4. 4
    Xue Qin Yu, Mark Clements, Dianne O’Connell, Projections of cancer prevalence by phase of care: a potential tool for planning future health service needs, Journal of Cancer Survivorship, 2013, 7, 4, 641

    CrossRef

  5. 5
    Valentina Casadio, Daniele Calistri, Samanta Salvi, Roberta Gunelli, Elisa Carretta, Dino Amadori, Rosella Silvestrini, Wainer Zoli, Urine Cell-Free DNA Integrity as a Marker for Early Prostate Cancer Diagnosis: A Pilot Study, BioMed Research International, 2013, 2013, 1

    CrossRef

  6. 6
    Xiaozhi Zheng, Ping Ji, Hongwei Mao, Jianqun Hu, A comparison of virtual touch tissue quantification and digital rectal examination for discrimination between prostate cancer and benign prostatic hyperplasia, Radiology and Oncology, 2012, 46, 1

    CrossRef

  7. 7
    C. Neppl-Huber, M. Zappa, J. W. Coebergh, E. Rapiti, J. Rachtan, B. Holleczek, S. Rosso, T. Aareleid, H. Brenner, A. Gondos, Changes in incidence, survival and mortality of prostate cancer in Europe and the United States in the PSA era: additional diagnoses and avoided deaths, Annals of Oncology, 2012, 23, 5, 1325

    CrossRef

  8. 8
    Jörg Ellinger, David C. Müller, Stefan C. Müller, Stefan Hauser, Lukas C. Heukamp, Alexander von Ruecker, Patrick J. Bastian, Gisela Walgenbach-Brunagel, Circulating mitochondrial DNA in serum: A universal diagnostic biomarker for patients with urological malignancies, Urologic Oncology: Seminars and Original Investigations, 2012, 30, 4, 509

    CrossRef

  9. 9
    Michael B. Nichol, Joanne Wu, Joice Huang, Dwight Denham, Stanley K. Frencher, Steven J. Jacobsen, Cost-effectiveness of Prostate Health Index for prostate cancer detection, BJU International, 2012, 110, 3
  10. 10
    Lissette Delgado-Cruzata, Gregory W. Hruby, Karina Gonzalez, James McKiernan, Mitchel C. Benson, Regina M. Santella, Jing Shen, DNA Methylation Changes Correlate with Gleason Score and Tumor Stage in Prostate Cancer, DNA and Cell Biology, 2012, 31, 2, 187

    CrossRef

  11. 11
    Brett Delahunt, Rose J Miller, John R Srigley, Andrew J Evans, Hemamali Samaratunga, Gleason grading: past, present and future, Histopathology, 2012, 60, 1
  12. 12
    Ji Chen, Yong Zhao, Xin Li, Peng Sun, Muwen Wang, Ridong Wang, Xunbo Jin, Imaging primary prostate cancer with 11C-Choline PET/CT: relation to tumour stage, Gleason score and biomarkers of biologic aggressiveness, Radiology and Oncology, 2012, 46, 3

    CrossRef

  13. 13
    Sepehr Nowfar, Ryan Kopp, Kerrin Palazzi-Churas, Ithaar H. Derweesh, Christopher J. Kane, Initial Experience with Aspirin Use During Robotic Radical Prostatectomy, Journal of Laparoendoscopic & Advanced Surgical Techniques, 2012, 22, 3, 225

    CrossRef

  14. 14
    Theodore E. Whitmore, Amelia Peterson, Ted Holzman, Ashley Eastham, Lynn Amon, Martin McIntosh, Adrian Ozinsky, Peter S. Nelson, Daniel B. Martin, Integrative Analysis of N-Linked Human Glycoproteomic Data Sets Reveals PTPRF Ectodomain as a Novel Plasma Biomarker Candidate for Prostate Cancer, Journal of Proteome Research, 2012, 11, 5, 2653

    CrossRef

  15. 15
    Qiujin Shen, Jia Fan, Xin-Rong Yang, Yexiong Tan, Weifeng Zhao, Yang Xu, Ning Wang, Yongdong Niu, Zheng Wu, Jian Zhou, Shuang-Jian Qiu, Ying-Hong Shi, Bin Yu, Ning Tang, Wei Chu, Min Wang, Jinhua Wu, Zhigang Zhang, Shengli Yang, Jianren Gu, Hongyang Wang, Wenxin Qin, Serum DKK1 as a protein biomarker for the diagnosis of hepatocellular carcinoma: a large-scale, multicentre study, The Lancet Oncology, 2012, 13, 8, 817

    CrossRef

  16. 16
    Francisco A. Conde, Wendy Landier, Dianne Ishida, Rose Bell, Charlene F. Cuaresma, Jane Misola, Barriers and Facilitators of Prostate Cancer Screening Among Filipino Men in Hawaii, Oncology Nursing Forum, 2011, 38, 2, 227

    CrossRef

  17. 17
    M B Nichol, J Wu, J J An, J Huang, D Denham, S Frencher, S J Jacobsen, Budget impact analysis of a new prostate cancer risk index for prostate cancer detection, Prostate Cancer and Prostatic Diseases, 2011, 14, 3, 253

    CrossRef

  18. 18
    John R. Waldeisen, Tim Wang, Benjamin M. Ross, Luke P. Lee, Disassembly of a Core–Satellite Nanoassembled Substrate for Colorimetric Biomolecular Detection, ACS Nano, 2011, 5, 7, 5383

    CrossRef

  19. 19
    Jamie Mitchell, Examining the Influence of Social Ecological Factors on Prostate Cancer Screening in Urban African-American Men, Social Work in Health Care, 2011, 50, 8, 639

    CrossRef

  20. 20
    Joanne M. Harrington, Implications of Treatment on Body Image and Quality of Life, Seminars in Oncology Nursing, 2011, 27, 4, 290

    CrossRef

  21. 21
    Ronald E. Myers, Constantine Daskalakis, Elisabeth J.S. Kunkel, James R. Cocroft, Jeffrey M. Riggio, Mark Capkin, Clarence H. Braddock, Mediated decision support in prostate cancer screening: A randomized controlled trial of decision counseling, Patient Education and Counseling, 2011, 83, 2, 240

    CrossRef

  22. You have free access to this content22
    C. Stewart Rogers, Perspective on prostate cancer screening, International Journal of Clinical Practice, 2011, 65, 1
  23. 23
    Ted A. Skolarus, Margaret Holmes-Rovner, Laurel L. Northouse, Angela Fagerlin, Carol Garlinghouse, Raymond Y. Demers, David R. Rovner, May Darwish-Yassine, John T. Wei, Primary care perspectives on Prostate cancer screening, The Nurse Practitioner, 2011, 36, 6, 39

    CrossRef

  24. 24
    Meelan Bul, Fritz H. Schröder, Screening for prostate cancer – The controversy continues, but can it be resolved?, Acta Oncologica, 2011, 50, S1, 4

    CrossRef

  25. 25
    Xinhua Xie, Jiaoli Guo, Yanan Kong, Gene Xianquan Xie, Laishen Li, Ning Lv, Xiangsheng Xiao, Jun Tang, Xi Wang, Peng Liu, Mingtian Yang, Zeming Xie, Weidong Wei, Xiaoming Xie, Targeted expression of Escherichia coli purine nucleoside phosphorylase and Fludara® for prostate cancer therapy, The Journal of Gene Medicine, 2011, 13, 12
  26. 26
    Mengqian Chen, Richard Carkner, Ralph Buttyan, The hedgehog/Gli signaling paradigm in prostate cancer, Expert Review of Endocrinology & Metabolism, 2011, 6, 3, 453

    CrossRef

  27. 27
    Richard M Hoffman, Anthony Y Smith, What we have learned from randomized trials of prostate cancer screening, Asian Journal of Andrology, 2011, 13, 3, 369

    CrossRef

  28. 28
    Theodore L. Johnson, Abdominal and back pain in a 65-year-old patient with metastatic prostate cancer, Journal of Chiropractic Medicine, 2010, 9, 1, 11

    CrossRef

  29. 29
    Michelle A. Angie, Accurate Use of Prostate-Specific Antigen in Determining Risk of Prostate Cancer, The Journal for Nurse Practitioners, 2010, 6, 3, 177

    CrossRef

  30. 30
    Ping Tang, Leon Sun, Matthew A. Uhlman, Thomas J. Polascik, Stephen J. Freedland, Judd W. Moul, Baseline PSA as a predictor of prostate cancer-specific mortality over the past 2 decades, Cancer, 2010, 116, 20
  31. 31
    Anastasia K. Yocum, Amjad P. Khan, Rong Zhao, Arul M. Chinnaiyan, Development of selected reaction monitoring-MS methodology to measure peptide biomarkers in prostate cancer, PROTEOMICS, 2010, 10, 19
  32. 32
    Shen-Chieh Chou, Manjinder Kaur, John A. Thompson, Rajesh Agarwal, Chapla Agarwal, Influence of Gallate Esterification on the Activity of Procyanidin B2 in Androgen-Dependent Human Prostate Carcinoma LNCaP Cells, Pharmaceutical Research, 2010, 27, 4, 619

    CrossRef

  33. 33
    Richard M Hoffman, Randomized trial results did not resolve controversies surrounding prostate cancer screening, Current Opinion in Urology, 2010, 20, 3, 189

    CrossRef

  34. 34
    Peter C. Albertsen, Reply, Urology, 2010, 75, 2, 405

    CrossRef

  35. 35
    Torstein Lindstad, Yang Jin, Ling Wang, Su Qu, Fahri Saatcioglu, STAMPs at the Crossroads of Cancer and Nutrition, Nutrition and Cancer, 2010, 62, 7, 891

    CrossRef

  36. 36
    J. Li, R. J. Coates, M. Gwinn, M. J. Khoury, Steroid 5- -Reductase Type 2 (SRD5a2) Gene Polymorphisms and Risk of Prostate Cancer: A HuGE Review, American Journal of Epidemiology, 2010, 171, 1, 1

    CrossRef

  37. 37
    TIMOTHY QUIGLEY, … PROSTATE CANCER SCREENING: Benefits and harms of widespread PSA test use still unclear, Journal of the American Academy of Physician Assistants, 2009, 22, 10, 50

    CrossRef

  38. 38
    Barbara Ercole, Ian M. Thompson, Prostate Cancer Prevention,